Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genocea Biosciences (NASDAQ:GNCA) and Bluebird Bio (NASDAQ:BLUE).
Genocea Biosciences (GNCA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Genocea Biosciences, with a price target of $5. The company’s shares opened today at $0.62, close to its 52-week low of $0.57.
Pantginis said:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.8% and a 31.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Genocea Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Bluebird Bio (BLUE)
In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Bluebird Bio. The company’s shares opened today at $151.50.
McCarthy commented:
“bluebird reported 2Q18 with $7.9M in revenue and a net loss of $146M. Operating expenses have increased as both gene therapy and CAR-T candidates move through later stages of development. The company ended the period with $1.46B in cash, excluding the $600M raised in a recent equity financing. Combined, bluebird has ~$2B in cash, runway into 2022.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 11.0% and a 43.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $214.43 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
